The effects of co-administration of Erlotinib and Apatinib in the treatment oesophageal Squamous Cell Carcinoma
- Publication Type:
- Conference Proceeding
- Annals of Oncology, 2021, 32, pp. S187-S187
- Issue Date:
|P-263 The effects of co-administration of erlotinib and apatinib in the treatment oesophageal squamous cell carcinoma - Annals of Oncology.pdf||Published version||145.81 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Background: Epidermal growth factor receptor (EGFR) and vascular EGFR (VEGFR) molecular characteristics have significant relevance to patient prognosis. The extensive crosstalk between EGFR and VEGFR signaling in oesophageal cancer provides a rationale for joint targeting of the two pathways using Erlotinib plus Apatinib. The aim of the current study was to investigate the clinical potentials and the underlying mechanism for the combinational use of Erlotinib and Apatinib in the treatment of oesophageal squamous cell carcinoma (ESCC) using our established ESCC patient-derived tumour xenograft models. Methods: According to the EGFR copy number gain (CNG) and EGFR mutation status, we established preclinical models which became refractory to Erlotinib. We then evaluated the effects of Apatinib, Erlotinib, and Erlotinib plus Apatinib on EGFR (mut+) xenograft model and EGFR (mut-) xenograft models. Results: The combined administration of Erlotinib and Apatinib showed strong tumour inhibiting effects on EGFR (mut+) ESCC xenografts. When Erlotinib or Apatinib was used alone, the ESCC tumour inhibitory effects were significantly weaker. In comparison, Erlotinib and Apatinib together were exclusively cytostatic with no more activity than either drug alone in the EGFR (mut-) xenografts. Conclusions: Our data demonstrates that combined therapy with Erlotinib and Apatinib shows promising efficacy in the treatment of ESCC in a xenograft model of EGFR (Mut+). Furthermore, reinduction of VEGF and subsequent VEGF-dependent tumour growth has been suggested as one of the major mechanisms of acquired resistance to Erlotinib. These findings provide a rationale for further clinical trials of the oesophageal cancer patients with mutant EGFR.
Please use this identifier to cite or link to this item: